Table 1.
The patient baseline characteristics (χ2 and Mann–Whitney test p values of the differences between the two study groups)
| All patients (n = 429) | TTBCG ≤ 101 days (n = 200; 46,6%) | TTBCG > 101 days (n = 229; 53,4%) | p value | |
|---|---|---|---|---|
| Age (median; IQR) | 67,1; 58–75 | 67,1; 58–74 | 67,0; 58–75 | 0.561 |
| Gender (M/F) | 349/80 (81.4/18.6%) | 161/39 (80.5/19.5%) | 188/41 (82,1/17,9%) | 0.672 |
| Smoking history; n (%) | 0.284 | |||
| Never | 138 (32.2%) | 68 (34%) | 70 (30.6%) | |
| Former | 179 (41.7%) | 75 (37.5%) | 104 (45.4%) | |
| Current | 103 (24%) | 51 (25.5%) | 52 (22.7%) | |
| UKN | 9 (2.1%) | 6 (3%) | 3 (1.3%) | |
| Concomitant CIS | 0.479 | |||
| Yes | 75 (17.5%) | 33 (16.6%) | 42 (18.3%) | |
| No | 352 (82.1%) | 167 (83.5%) | 185 (80.8%) | |
| UKN | 2 (0.5%) | 2 (0.9%) | ||
| Tumor size | 0.152 | |||
| < 3 cm | 197 (45.9%) | 99 (49.5) | 98 (42.8%) | |
| ≥ 3 cm | 201 (46,9%) | 84 (42%) | 117 (51,1%) | |
| UKN | 31 (7.2%) | 17 (8.5%) | 14 (6.1%) | |
| Tumor focality | 0.472 | |||
| Solitary | 191 (44.5%) | 93 (46.5%) | 98 (42.8%) | |
| Multiple | 214 (49.9%) | 94 (47%) | 120 (52.4%) | |
| UKN | 24 (5.6%) | 13 (6.5%) | 11 (4.8%) | |
| Muscularis propria in the primary specimen (yes/no) | 307/100/22 (71.6/23.3/5.1%) | 144/43/13 (72/21.5/6.5%) | 163/57/9 (71.2/24.9/3.9%) | 0.385 |
| Residual disease at reTURB (yes/no) | 163/266 (38/62%) | 62/138 (31/69%) | 101/128 (44.1/55.9%) | 0.005 |
| Muscularis propria in the reTURB specimen | 0.925 | |||
| Yes | 286 (66.7%) | 134 (67%) | 152 (66.4%) | |
| No | 123 (28.7%) | 56 (28%) | 67 (29.3%) | |
| UKN | 20 (4.7%) | 10 (5%) | 10 (4.4%) | |
| BCG strain; n (%) | 0.019 | |||
| Moreau | 99 (23.1%) | 58 (29%) | 41 (17.9%) | |
| TICE | 169 (39.4%) | 66 (33%) | 103 (45%) | |
| RIVM | 118 (27.5%) | 54 (27%) | 64 (27.9%) | |
| Other | 43 (10%) | 22 (11%) | 21 (9.2%) | |
| Total number of BCG instillations (median; IQR) | 15; 9–18 | 15; 9–18 | 15; 9–16 | 0.211 |
| Observation time – months (median; IQR) | 40; 24–58 | 36,1; 23–56 | 43,9; 25–62 | 0.023 |
| Recurrence | 144 (33.6%) | 59 (29.5%) | 85 (37.1%) | 0.096 |
| Progression | 61 (14.2%) | 37 (18.5%) | 24 (10.5%) | 0.018 |
| Cancer specific death | 33 (7.7%) | 19 (9.5%) | 14 (6.1%) | 0.189 |
The value of adjusted p < 0.05 was considered statistically significant (bolded)
IQR interquartile range, M male, F female, CIS carcinoma in situ, UKN unknown